On October 13th, 2011, Hualan Biological Engineering Inc. (002007.SZ) annouced that the second flu vaccine workshop and the No. 4, No.5, No.6 packaging lines in packaging section 2 of its subsidiary Hualan Biological Vaccine Co., Ltd. complied with the requirements of new GMP, thus passed through the GMP authentication, and were granted certificates CN20110018 and CN20110016 respectively. After passing through the new GMP authentication, the company may apply to WHO for prequalification, which means the possibility to open up the international market.
In H1 2011, Hualan Biological achieved RMB 41 million of operation revenue from vaccine business, up 38.9% YoY. Depending on advantages such as rich presently-owned vaccines and vaccines under research and the new GMP authentication, it is predicted that the vaccine business will contribute more to the company’s business performance. However, the WHO prequalification will take long, therefore, it will have little impact on the business performance this year.
Existing Vaccines and Vaccines under Research of Hualan Biological, As of Sep.2011
|
Existing Products
|
Flu virus cracking vaccine (adult dosage form), recombinant hepatitis b vaccine (Hansenula), flu virus cracking vaccine (child dosage form), ACYW135-group meningococcal polysaccharide vaccine c, A H1N1 flu virus cracking vaccine
|
|
Products under Research
|
HFMD EV71 virus inactivated vaccine, combined DTP-HBV-HIB vaccine, pneumococcal vaccine, general flu vaccine, etc.
|
Source: Hualan Biological; ResearchInChina